Treatment of high risk myelodysplastic syndrome
The myelodysplastic syndrome (MDS) is considered to be a heterogeneous myeloid malignancy with a common origin in the hematopoietic stem cell compartment, generally divided into lower and higher risk. While treatment goal for lower risk MDS (LR-MDS) is to decrease transfusion burden and transformat...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ferrata Storti Foundation
2024-12-01
|
| Series: | Haematologica |
| Online Access: | https://haematologica.org/article/view/11858 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|